Agnieszka Konopacka

Agnieszka Konopacka is a drug discovery Group Leader at the Institute of Cancer Research - Centre for Protein Degradation in London. She has received her PhD in Medical Sciences in 2008 from the Mossakowski Medical Research Centre in Warsaw and completed postdoctoral training at Bristol University. Since 2014 she was associated with pharma industry including Pfizer, Horizon Discovery and GSK Protein Degradation Group pioneering innovative drug discovery technologies, where she led multiple initiatives in oncology, immuno-oncology and immunology portfolio. In 2024 she joined the ICR to lead biology at the CPD. Her research team focuses on discovery of novel molecular glues and PROTAC degraders and enabling novel E3 ligases for cancer therapy, and provides comprehensive drug discovery platforms for target validation, cell-based screening, mechanistic profiling, and in vitro efficacy studies. She is a Vice-Chair of the Society for Medicines Research and a member of Women in TPD group.